GlassScriptPhysician profile
John M Lesher
NPI 1063440634
$5,431.88
in general payments reported to CMS, 2019-2025
40 companies · $1,876 in 2025
The $1,876 reported for 2025 was more than what 93% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.15 · 2022: $152 · 2023: $789 · 2024: $2,578 · 2025: $1,876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,300 · Travel and Lodging: $1,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,300.48 |
| Travel and Lodging | $1,942.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $1,260.44 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Spr Therapeutics, INC | $1,108.38 | 2023-2025 | Sprint Pns System |
| Boston Scientific Corporation | $328.29 | 2024-2025 | Na, General - Pain Management, General - Therapies |
| Novo Nordisk INC | $280.17 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Ibsa Pharma INC. | $226.43 | 2023-2025 | Licart, Tirosint, Tirosint |
| Janssen Biotech, INC. | $222.52 | 2024-2025 | Tremfya |
| Saluda Medical Americas, INC. | $201.28 | 2023 | Evoke Scs |
| Abbott Laboratories | $152.02 | 2022-2025 | Proclaim, Freestyle Libre 3, Eterna |
| Sonex Health, INC. | $144.24 | 2021-2022 | |
| Painteq LLC | $139.66 | 2023 | Painteq |
| Takeda Pharmaceuticals U.S.A., INC. | $139.54 | 2023-2025 | Entyvio |
| Amneal Pharmaceuticals LLC | $127.64 | 2023-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $116.19 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.61 | 2024-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $86.61 | 2025 | Rezdiffra |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $81.33 | 2023-2025 | |
| Amgen INC. | $80.10 | 2023-2024 | Evenity, Prolia |
| Orthofundamentals, LLC | $74.58 | 2025 | Trellis Si Joint Fusion System |
| Aimmune Therapeutics, INC. | $72.60 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $50.30 | 2025 | Dupixent |
| Xeris Pharmaceuticals, INC. | $31.98 | 2025 | Gvoke Hypopen |
| Cequr Corporation | $30.53 | 2024-2025 | Cequr Simplicity |
| Vertex Pharmaceuticals Incorporated | $28.79 | 2025 | |
| Pfizer INC. | $28.67 | 2025 | |
| Trice Medical, INC. | $27.77 | 2024 | |
| Nevro Corp. | $27.61 | 2024 | Senza |
| Daiichi Sankyo INC. | $27.31 | 2023 | Injectafer |
| Sequel Med Tech, LLC | $26.27 | 2025 | Twiist |
| Lundbeck LLC | $24.17 | 2022 | |
| Dexcom, INC. | $23.68 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $22.61 | 2025 | Korlym |
| Beta Bionics, INC. | $21.97 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Tandem Diabetes Care, INC. | $19.91 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ferring Pharmaceuticals INC. | $19.18 | 2024 | Euflexxa |
| Bioventus LLC | $17.78 | 2025 | Xcell |
| Acella Pharmaceuticals, LLC | $15.30 | 2025 | NP Thyroid 60 |
| Lilly USA, LLC | $14.57 | 2025 | Jardiance |
| Redhill Biopharma INC. | $14.34 | 2023 | Talicia |
| Bayer Healthcare Pharmaceuticals INC. | $13.92 | 2025 | |
| Echosens North America, INC. | $12.59 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lesher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.